TKTX Company sells unapproved, misbranded lidocaine numbing creams online at illegal concentrations for cosmetic procedures.
What happened
FDA reviewed the website https://tktxcompany.com/, where the four numbing creams were available for purchase, and found them marketed as external analgesics for use before or during cosmetic procedures. FDA determined the products are unapproved new drugs and misbranded because their lidocaine concentrations exceed the OTC external analgesic monograph range and some ingredients, combinations, or indications are not allowed. FDA also cited safety concerns about greater absorption through irritated or broken skin during cosmetic procedures.
What FDA found
The products are unapproved new drugs because they are marketed without an FDA-approved application and do not meet the OTC monograph requirements.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The products are misbranded because they are nonprescription drugs subject to section 505G but do not comply with that section and are not approved under section 505.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)The labels list lidocaine at 22%, 10%, 8%, and 29.9%, all above the 0.5% to 4% range permitted by the OTC external analgesic monograph.
Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355hThe products use lidocaine with epinephrine, prilocaine, or tetracaine in combinations or ingredients not permitted by the OTC external analgesic monograph.
Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355hThe labeling includes uses such as tattooing and laser cosmetic procedures that are not included in the OTC external analgesic monograph or any final administrative order.
Over-the-Counter Monograph M017; section 505G of the FD&C Act, 21 U.S.C. 355h
What FDA wants
FDA asks the company to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations, including how recurrence will be prevented and related documentation. If corrective action cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- online sellers of numbing creams
- tattoo and permanent makeup clinics
- brands importing topical anesthetics from China
This is a summary. Read the original letter on fda.gov.